Eli Lilly and Company (LLY) – Investment Analysts’ Weekly Ratings Updates

A number of research firms have changed their ratings and price targets for Eli Lilly and Company (NYSE: LLY):

• 6/9/2026 – Eli Lilly and Company had its price target raised by Jefferies Financial Group Inc. from $1,330.00 to $1,350.00. They now have a “buy” rating on the stock.
• 6/8/2026 – Eli Lilly and Company had its “outperform” rating reaffirmed by Sanford C. Bernstein.
• 6/5/2026 – Eli Lilly and Company had its “overweight” rating reaffirmed by Morgan Stanley.
• 5/26/2026 – Eli Lilly and Company had its price target raised by Bank of America Corporation from $1,133.00 to $1,251.00. They now have a “buy” rating on the stock.
• 5/26/2026 – Eli Lilly and Company was given a new $1,119.00 price target by Leerink Partners.
• 5/22/2026 – Eli Lilly and Company had its “buy” rating reaffirmed by The Goldman Sachs Group, Inc.. They now have a $1,283.00 price target on the stock.
• 5/21/2026 – Eli Lilly and Company had its “outperform” rating reaffirmed by Wolfe Research. They now have a $1,350.00 price target on the stock.
• 5/21/2026 – Eli Lilly and Company had its “outperform” rating reaffirmed by Royal Bank Of Canada.
• 5/21/2026 – Eli Lilly and Company had its price target raised by Jefferies Financial Group Inc. from $1,300.00 to $1,330.00.
• 5/19/2026 – Eli Lilly and Company was downgraded by Weiss Ratings from “buy (b)” to “buy (b-)”.
• 5/7/2026 – Eli Lilly and Company had its price target raised by Rothschild & Co Redburn from $880.00 to $900.00.
• 5/5/2026 – Eli Lilly and Company had its “buy” rating reaffirmed by Guggenheim. They now have a $1,183.00 price target on the stock.
• 5/4/2026 – Eli Lilly and Company was upgraded by Weiss Ratings from “buy (b-)” to “buy (b)”.
• 5/4/2026 – Eli Lilly and Company had its “outperform” rating reaffirmed by Wolfe Research. They now have a $1,325.00 price target on the stock.
• 5/4/2026 – Eli Lilly and Company had its price target raised by Barclays PLC from $1,350.00 to $1,400.00. They now have an “overweight” rating on the stock.
• 5/2/2026 – Eli Lilly and Company was upgraded by Wall Street Zen from “buy” to “strong-buy”.
• 5/1/2026 – Eli Lilly and Company had its “overweight” rating reaffirmed by Morgan Stanley. They now have a $1,344.00 price target on the stock.
• 5/1/2026 – Eli Lilly and Company had its “outperform” rating reaffirmed by Royal Bank Of Canada.
• 5/1/2026 – Eli Lilly and Company had its price target lowered by Bank of America Corporation from $1,294.00 to $1,133.00. They now have a “buy” rating on the stock.
• 5/1/2026 – Eli Lilly and Company had its price target raised by Cantor Fitzgerald from $1,205.00 to $1,230.00. They now have an “overweight” rating on the stock.
• 5/1/2026 – Eli Lilly and Company had its price target raised by The Goldman Sachs Group, Inc. from $1,260.00 to $1,283.00. They now have a “buy” rating on the stock.
• 4/27/2026 – Eli Lilly and Company had its price target lowered by Leerink Partners from $1,296.00 to $1,058.00. They now have an “outperform” rating on the stock.
• 4/21/2026 – Eli Lilly and Company had its price target raised by Guggenheim from $1,163.00 to $1,183.00. They now have a “buy” rating on the stock.

Eli Lilly and Company Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Wednesday, June 10th. Shareholders of record on Friday, May 15th were issued a dividend of $1.73 per share. The ex-dividend date was Friday, May 15th. This represents a $6.92 annualized dividend and a yield of 0.6%. Eli Lilly and Company’s payout ratio is currently 24.58%.

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.